CAR‐T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph+ mixed phenotype acute leukaemia with minimal residual disease
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16982
Abstract: increased risk of morbidity and mortality. In the HERCULES phase 3 trial, treatment with caplacizumab in patients with TTP has been shown to normalize platelets with a median time of 2 69 days [95% confidence… read more here.
Keywords: therapy bridging; refractory ttp; therapy; car therapy ... See more keywords